| pubmed-article:12352131 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12352131 | lifeskim:mentions | umls-concept:C0206194 | lld:lifeskim |
| pubmed-article:12352131 | lifeskim:mentions | umls-concept:C0001675 | lld:lifeskim |
| pubmed-article:12352131 | lifeskim:mentions | umls-concept:C0006434 | lld:lifeskim |
| pubmed-article:12352131 | lifeskim:mentions | umls-concept:C0205082 | lld:lifeskim |
| pubmed-article:12352131 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:12352131 | lifeskim:mentions | umls-concept:C0205216 | lld:lifeskim |
| pubmed-article:12352131 | lifeskim:mentions | umls-concept:C0023303 | lld:lifeskim |
| pubmed-article:12352131 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:12352131 | lifeskim:mentions | umls-concept:C0758247 | lld:lifeskim |
| pubmed-article:12352131 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:12352131 | pubmed:dateCreated | 2002-9-27 | lld:pubmed |
| pubmed-article:12352131 | pubmed:abstractText | Mortality and length of stay (LOS) of survivors was examined retrospectively in 270 adults with acute burns > or =20% of body surface area to determine the effect of Integra Dermal Regeneration Template treatment on outcome. No difference in mortality was found between patients who received Integra (30%; n = 43) and patients who did not (30%; n = 227). Surviving Integra patients (n = 30) stayed longer, but they were more extensively injured than survivors who did not receive Integra (n = 158), and therefore longer hospitalizations were expected. In a subgroup analysis, mean LOS of Integra patients with two or more mortality risk factors (age > 60 years, burn size >40% body surface area, or inhalation injury; n = 15) was 63 days compared with 107 days in patients with two or more risk factors (n = 29) who did not receive Integra ( =.014). Integra use in severely injured burned adults was associated with a marked decrease in LOS. | lld:pubmed |
| pubmed-article:12352131 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12352131 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12352131 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12352131 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12352131 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12352131 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12352131 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12352131 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12352131 | pubmed:issn | 0273-8481 | lld:pubmed |
| pubmed-article:12352131 | pubmed:author | pubmed-author:SheridanRober... | lld:pubmed |
| pubmed-article:12352131 | pubmed:author | pubmed-author:RyanColleen... | lld:pubmed |
| pubmed-article:12352131 | pubmed:author | pubmed-author:TompkinsRonal... | lld:pubmed |
| pubmed-article:12352131 | pubmed:author | pubmed-author:SchoenfeldDav... | lld:pubmed |
| pubmed-article:12352131 | pubmed:author | pubmed-author:MalloyMaryann... | lld:pubmed |
| pubmed-article:12352131 | pubmed:author | pubmed-author:SchulzJohn... | lld:pubmed |
| pubmed-article:12352131 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12352131 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:12352131 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12352131 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12352131 | pubmed:pagination | 311-7 | lld:pubmed |
| pubmed-article:12352131 | pubmed:dateRevised | 2006-8-15 | lld:pubmed |
| pubmed-article:12352131 | pubmed:meshHeading | pubmed-meshheading:12352131... | lld:pubmed |
| pubmed-article:12352131 | pubmed:meshHeading | pubmed-meshheading:12352131... | lld:pubmed |
| pubmed-article:12352131 | pubmed:meshHeading | pubmed-meshheading:12352131... | lld:pubmed |
| pubmed-article:12352131 | pubmed:meshHeading | pubmed-meshheading:12352131... | lld:pubmed |
| pubmed-article:12352131 | pubmed:meshHeading | pubmed-meshheading:12352131... | lld:pubmed |
| pubmed-article:12352131 | pubmed:meshHeading | pubmed-meshheading:12352131... | lld:pubmed |
| pubmed-article:12352131 | pubmed:meshHeading | pubmed-meshheading:12352131... | lld:pubmed |
| pubmed-article:12352131 | pubmed:meshHeading | pubmed-meshheading:12352131... | lld:pubmed |
| pubmed-article:12352131 | pubmed:meshHeading | pubmed-meshheading:12352131... | lld:pubmed |
| pubmed-article:12352131 | pubmed:meshHeading | pubmed-meshheading:12352131... | lld:pubmed |
| pubmed-article:12352131 | pubmed:meshHeading | pubmed-meshheading:12352131... | lld:pubmed |
| pubmed-article:12352131 | pubmed:meshHeading | pubmed-meshheading:12352131... | lld:pubmed |
| pubmed-article:12352131 | pubmed:meshHeading | pubmed-meshheading:12352131... | lld:pubmed |
| pubmed-article:12352131 | pubmed:meshHeading | pubmed-meshheading:12352131... | lld:pubmed |
| pubmed-article:12352131 | pubmed:meshHeading | pubmed-meshheading:12352131... | lld:pubmed |
| pubmed-article:12352131 | pubmed:meshHeading | pubmed-meshheading:12352131... | lld:pubmed |
| pubmed-article:12352131 | pubmed:meshHeading | pubmed-meshheading:12352131... | lld:pubmed |
| pubmed-article:12352131 | pubmed:meshHeading | pubmed-meshheading:12352131... | lld:pubmed |
| pubmed-article:12352131 | pubmed:articleTitle | Use of Integra artificial skin is associated with decreased length of stay for severely injured adult burn survivors. | lld:pubmed |
| pubmed-article:12352131 | pubmed:affiliation | Department of Surgery, Sumner Redstone Center, Massachusetts General Hospital, Boston, MA 02114, USA. | lld:pubmed |
| pubmed-article:12352131 | pubmed:publicationType | Journal Article | lld:pubmed |
